Kura Oncology (KURA) Invested Capital (2010 - 2026)

Kura Oncology (KURA) has 17 years of Invested Capital data on file, last reported at $107.9 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $107.9 million, down 70.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.9 million (down 70.55% YoY), and the FY2025 annual result was $183.8 million, down 55.84% from the prior year.
• Invested Capital declined to $107.9 million in Q1 2026 per KURA's latest filing, from $183.8 million in the prior quarter.
• Over five years, Invested Capital peaked at $505.1 million in Q1 2024 and troughed at $107.9 million in Q1 2026.
• A 5-year average of $380.9 million and a median of $419.6 million in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2026: Invested Capital gained 27.81% in 2024, then plunged 70.55% in 2026.
• A 5-year view of Invested Capital shows it stood at $420.3 million in 2022, then declined by 5.47% to $397.3 million in 2023, then rose by 4.78% to $416.2 million in 2024, then slumped by 55.84% to $183.8 million in 2025, then plunged by 41.32% to $107.9 million in 2026.
• Business Quant data shows KURA's Invested Capital at $107.9 million in Q1 2026, $183.8 million in Q4 2025, and $246.9 million in Q3 2025.